Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 17/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2465356 | 0.89 | OPRD1 (0.53) | OPRD1OPRK1OPRM1 | |
| SCHEMBL2468057 | 0.83 | OPRD1 (0.50) | OPRD1OPRK1OPRM1APP | |
| SCHEMBL2468263 | 0.83 | OPRD1 (0.60) | OPRD1OPRK1OPRM1APP | |
| SCHEMBL2468270 | 0.82 | OPRD1 (0.48) | OPRD1OPRK1OPRM1APP | |
| SCHEMBL13688445 | 0.81 | OPRD1 (0.52) | OPRD1OPRK1OPRM1 | |
| SCHEMBL2491525 | 0.81 | OPRD1 (0.55) | OPRD1OPRK1OPRM1APP | |
| SCHEMBL2466761 | 0.81 | OPRD1 (0.51) | OPRD1OPRK1OPRM1 | |
| SCHEMBL2473455 | 0.81 | OPRD1 (0.53) | OPRD1OPRK1OPRM1TP53APP | |
| SCHEMBL2471279 | 0.81 | OPRD1 (0.65) | OPRD1OPRK1OPRM1 | |
| SCHEMBL2465745 | 0.80 | OPRD1 (0.65) | OPRD1OPRK1OPRM1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | LLOYD JOHN | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014792-A1 | Heterocyclo inhibitors of potassium channel function | KCNJ2, KCNH2, KCNQ5 | OPRD1 2240/4885OPRK1 513/4885OPRM1 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.